Literature DB >> 9085143

Morphine and muscle relaxants are receptor-independent G-protein activators and cromolyn is an inhibitor of stimulated G-protein activity.

J F Klinker1, R Seifert.   

Abstract

Morphine and muscle relaxants are classical mast cell activators and cromolyn is a mast cell inhibitor. However, the mechanisms underlying the effects of these drugs are obscure. We asked the question whether morphine and muscle relaxants may activate heterotrimeric guanine nucleotide-binding proteins (G-proteins), and whether cromolyn may prevent this activation. Morphine activated Gi-proteins in HL-60 membranes and purified transducin (TD) at concentrations above 1 mM, but the effects on morphine did not reach saturation up to 10 mM. d-Tubocurarine activated Gi-proteins and TD in a saturable manner, with EC50 values of 0.3 mM and 4.2 mM, respectively. Gallamine and succinylcholine were less effective activators of TD than d-tubocurarine, Morphine and d-tubocurarine were about similarly effective activators of Gi-proteins, whereas d-tubocurarine was a more effective activator of TD than morphine. Cromolyn at 10 microM and 100 microM had little effect on TD activity but reduced the stimulatory effect of morphine by 50% and 80%, respectively. Our data suggest the following: (1) Receptor-independent G-protein activation by morphine and muscle relaxants presumably accounts for their mast cell-activating properties. (2) Cromolyn may act by preventing G-protein activation. (3) The variability in responsiveness of mast cells towards morphine and muscle relaxants could be due to differential expression of G-proteins with different sensitivity to activation by these drugs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9085143     DOI: 10.1007/s000110050058

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  7 in total

1.  Carbon-fiber microelectrode amperometry reveals sickle-cell-induced inflammation and chronic morphine effects on single mast cells.

Authors:  Benjamin M Manning; Robert P Hebbel; Kalpna Gupta; Christy L Haynes
Journal:  ACS Chem Biol       Date:  2012-01-23       Impact factor: 5.100

Review 2.  Exploring the link between pholcodine exposure and neuromuscular blocking agent anaphylaxis.

Authors:  Anna M Brusch; Russell C Clarke; Peter R Platt; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

3.  Opioid signaling in mast cells regulates injury responses associated with heterotopic ossification.

Authors:  Lixin Kan; Amelia A Mutso; Tammy L McGuire; Apkar Vania Apkarian; John A Kessler
Journal:  Inflamm Res       Date:  2013-12-11       Impact factor: 4.575

4.  Role of meningeal mast cells in intrathecal morphine-evoked granuloma formation.

Authors:  Tony L Yaksh; Jeffery W Allen; Samantha L Veesart; Kjersti A Horais; Shelle A Malkmus; Miriam Scadeng; Joanne J Steinauer; Steve S Rossi
Journal:  Anesthesiology       Date:  2013-03       Impact factor: 7.892

5.  Norepinephrine-induced cardiac hypertrophy and fibrosis are not due to mast cell degranulation.

Authors:  Wilfried Briest; Beate Rassler; Alexander Deten; Heinz-Gerd Zimmer
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

6.  Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation.

Authors:  Andrea M Siegel; Kelly D Stone; Glenn Cruse; Monica G Lawrence; Ana Olivera; Mi-yeon Jung; John S Barber; Alexandra F Freeman; Steven M Holland; Michelle O'Brien; Nina Jones; Celeste G Nelson; Laura B Wisch; Heidi H Kong; Avanti Desai; Orly Farber; Alasdair M Gilfillan; Juan Rivera; Joshua D Milner
Journal:  J Allergy Clin Immunol       Date:  2013-11-01       Impact factor: 10.793

Review 7.  Opioids: Modulators of angiogenesis in wound healing and cancer.

Authors:  Martina Ondrovics; Andrea Hoelbl-Kovacic; Daniela Alexandra Fux
Journal:  Oncotarget       Date:  2017-04-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.